ERBB2 and breast carcinoma: The anticancer activity of the studied compounds (3a–h) was explored with regards to two human breast cancer cell lines, namely the estrogen receptor positive (ER+) MCF-7 cells and the triple negative MDA-MB-231 cells (ER-, PR-, and HER-2/Neu-).